Beta

Vtv therapeutics inc.VTVT.US Overview

US StockHealthcare
(No presentation for VTVT)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

VTVT AI Insights

VTVT Overall Performance

VTVT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VTVT Recent Performance

8.74%

Vtv therapeutics inc.

-1.10%

Avg of Sector

-0.49%

S&P500

VTVT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check VTVT's Trend

VTVT Key Information

VTVT Valuation Metrics

VTVT Profile

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Price of VTVT

VTVT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VTVT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.31
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14852.65
PB Ratio
1.99
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-138058.82%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.31
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14852.65
PB Ratio
1.99
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-138058.82%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is VTVT's latest earnings report released?

    The most recent financial report for Vtv therapeutics inc. (VTVT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VTVT's short-term business performance and financial health. For the latest updates on VTVT's earnings releases, visit this page regularly.

  • How is VTVT's revenue growth?

    In the latest financial report, Vtv therapeutics inc. (VTVT) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does VTVT have?

    At the end of the period, Vtv therapeutics inc. (VTVT) held Total Cash and Cash Equivalents of 88.93M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does VTVT go with three margins increasing?

    In the latest report, Vtv therapeutics inc. (VTVT) achieved the “three margins increasing” benchmark, with a gross margin of 50%%, operating margin of 32,854.17%%, and net margin of 29,741.67%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VTVT's profit trajectory and future growth potential.

  • Is VTVT's EPS continuing to grow?

    According to the past four quarterly reports, Vtv therapeutics inc. (VTVT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.4. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VTVT?

    Vtv therapeutics inc. (VTVT)'s Free Cash Flow (FCF) for the period is -9.25M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 91.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VTVT?

    The latest valuation data shows Vtv therapeutics inc. (VTVT) has a Price-To-Earnings (PE) ratio of -5.11 and a Price/Earnings-To-Growth (PEG) ratio of 0.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.